Cabaletta’s CAR T-cell therapy cleared for SLE Phase 1/2 trial

The U.S. Food and Drug Administration (FDA) has cleared a Phase 1/2 clinical trial to test CABA-201, Cabaletta Bio’s investigational CAR T-cell therapy, in people with systemic lupus erythematosus (SLE) with or without kidney involvement. Cabaletta asked to launch the trial in the form of an investigational new…

CAR T-cell Therapy Drives Disease Remission for 5 SLE Patients

A CAR T-cell therapy targeting disease-driving immune cells safely led to sustained disease remission for five people with systemic lupus erythematosus (SLE) who’d previously failed to respond to other treatments, a recent study reported. Treatment was also highly specific, preventing autoimmune activity, but didn’t impair general immune system…

CAR T-cell Therapy Has Potential to Combat Lupus, Mouse Study Shows

Eliminating B-cells using a recent form of immunotherapy that employs genetically modified T-cells is able to treat lupus in mice in a stable and efficient way, a study funded by Lupus Research Alliance shows.